Earnings call briefThird-quarter 2026
Merck says 2027 will be a year of investment with moderate revenue growth
Merck said more than $2 billion of generic and loss-of-exclusivity headwinds in 2027 will partly offset growth from new launches and animal health.
GetSignal Merck MRK
On its third-quarter call, Chief Financial Officer Caroline Litchfield said Merck expects 2027 to be a year of investment behind its pipeline and launches, with moderate top-line growth. Merck expects underlying operating expenses to increase at a mid to high single digit rate.
The company said gross margin will rise as a Keytruda royalty rolls off.
Quotes from the call
“...in 2027, we expect moderate top line growth, and that is as a result of the strong contributions we expect from our new product launches, as well as animal health, that will be partially offset by more than $2 billion of headwinds...”
Key facts from the call
- Expected 2027 revenue outlook
- Moderate top-line growth
- Expected 2027 generic and loss-of-exclusivity headwinds
- More than $2 billion
- Expected 2027 underlying operating expense growth
- Mid to high single digit rate
Source: Merck's third-quarter 2026 earnings call, October 29, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
